- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05027087
The Effect of a Novel Blueberry Supplement on Dry Eye Disease (PLUM)
The Effect of a Novel Blueberry Supplement on Dry Eye Disease (PLUM)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Waterloo, Ontario, Canada, N2L 3G1
- Centre for Ocular Research & Education
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A person is eligible for inclusion in the study if he/she:
- Is at least 18 years of age and has full legal capacity to volunteer;
- Has read and signed an information consent letter;
- Is willing and able to follow instructions and maintain the appointment schedule;
- Is willing and anticipates to be able to comply with the daily intake of 3 gummy bears twice daily for 4 weeks;
As per TFOS DEWS II13, has dry eye symptoms as determined by an OSDI score ≥ 13 OR DEQ-5 ≥ 6, and at least one of the following:
- Tear film osmolarity ≥ 308 mOsm/L or interocular difference > 8 mOsm/L
- Non-invasive tear film break-up time of <10 seconds in at least one eye
- More than 5 spots of corneal staining OR > 9 conjunctiva spots OR lid margin staining (≥ 2mm length & ≥ 25% width) in at least one eye.
Exclusion Criteria:
A person will be excluded from the study if he/she:
- Is participating in any concurrent clinical or research study;
- Currently wears, or has worn contact lenses in the past 3 months;
Has symptoms/ signs of severe dry eye, defined by an OSDI score ≥ 33 and at least one of the following:
- Corneal staining grade ≥ 3 (Oxford scale)
- Non-invasive tear film break-up time of ≤ 3 seconds in at least one eye;
- Has any known active* ocular disease and/or infection;
- Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
- Is using any systemic or topical medications (including topical corticosteroids/ NSAIDs or glaucoma medications) that in the opinion of the investigator may affect a study outcome variable;
- Is currently taking, or has taken, any supplements containing anti-oxidants in the last three months;
- Has started taking omega-3 supplements within the last 3 months or intend to start them during the study;
- Has a known sensitivity or an allergy to ingredients of the gummy bears;
- Has been diagnosed with glucose-6-phosphate dehydrogenase (G6PD) deficiency;
- Has a known sensitivity to the diagnostic pharmaceuticals to be used in the study;
- Is pregnant, lactating or planning a pregnancy at the time of enrolment (by self-report);
- Has undergone refractive error surgery or intraocular surgery;
- Is a member of CORE directly involved in the study;
Has taken part in another (pharmaceutical) research study within the last 30 days.
- For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and mild dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Participants receive the blueberry gummy supplement
|
Gummy bear containing blueberry powder
|
Placebo Comparator: Placebo
Participant receive the placebo gummy supplement
|
Gummy bear with no active ingredients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in ODSI score from Baseline
Time Frame: 4 weeks
|
The Ocular Surface Disease Index (OSDI) is a 12-question validated questionnaire used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision.
The OSDI scoring scale ranges from 0 to 100.
The lower the score, the more symptomatic relief from dry eye symptoms a patient experiences.
Change between the score at baseline and the score at 4 weeks is reported.
|
4 weeks
|
Change in Non-Invasive Tear Break-Up Time (NITBUT) from Baseline
Time Frame: 4 weeks
|
The time required for a dry spot to appear on the corneal surface after blinking is referred to as the tear film break-up time.
The change in this time (measured in seconds) between baseline and 4 weeks is reported.
|
4 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 43221
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Singapore National Eye CentreCompleted
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Singapore National Eye CentreCompleted
Clinical Trials on Blueberry gummy
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales S.A.Completed
-
Purdue UniversityUnknownOsteoporosis, Postmenopausal | Bone Loss, Age-relatedUnited States
-
Ohio State UniversityActive, not recruitingOral Cancer | Oral Health | Gum DiseaseUnited States
-
Duke UniversityU.S. Highbush Blueberry CouncilCompletedSedentary Lifestyle | Blood Pressure | Overweight and Obesity | Arterial StiffnessUnited States
-
University of Mississippi Medical CenterU.S. Highbush Blueberry CouncilCompleted
-
Atlantic Food and Horticulture Research CenterDalhousie University; U.S. Highbush Blueberry CouncilCompleted
-
University of ReadingNaurex, Inc, an affiliate of Allergan plcCompletedCognitive DeclineUnited Kingdom
-
Appalachian State UniversityNorth Carolina State University; SinnovaTekCompleted
-
Northumbria UniversityCompletedCognitive Change | Blood Pressure | Vascular StiffnessUnited Kingdom
-
University of California, DavisCompleted